O-isopropyl 2-tert-butoxy-5-fluorophenylthiocarbamate | 663925-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: O-isopropyl 2-tert-butoxy-5-fluorophenylthiocarbamate
• 英文别名: (2-tert-butoxy-5-fluoro-phenyl)-thiocarbamic acid O-isopropyl ester；O-isopropyl N-(2-tert-butoxy-5-fluorophenyl)carbamothioate；O-propan-2-yl N-[5-fluoro-2-[(2-methylpropan-2-yl)oxy]phenyl]carbamothioate
• CAS: 663925-82-4
• 化学式: C₁₄H₂₀FNO₂S
• 分子量: 285.383
• InChiKey: CEADAORREOCYEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-isopropyl 2-tert-butoxy-5-fluorophenylthiocarbamate 在 N,O-双三甲硅基乙酰胺 、 (1R,2S)-1-氨基-2-茚醇 、 硼烷 、 叔丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 正戊烷 为溶剂， 反应 44.25h， 生成
  参考文献：
  名称：

  The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist

  摘要：

  The optimisation of two series of 4-hydroxybenzothiazolone derived β2-adrenoceptor agonists, bearing α-substituted cyclopentyl and β-phenethyl amino-substituents, as inhaled long-acting bronchodilators is described. Analogues were selected for synthesis using a lipophilicity based hypothesis to achieve the targeted rapid onset of action in combination with a long duration of action. The profiling of the two series led to identification of the α-substituted cyclopentyl analogue 2 as the optimal compound with a comparable profile to the inhaled once-daily long-acting β2-adrenoceptor agonist indacaterol. On the basis of these data 2 was promoted as the backup development candidate to indacaterol from the Novartis LABA project.

  DOI：

  10.1016/j.bmcl.2014.06.014
• 作为产物：
  描述：

  2-叔丁氧基-5-氟苯胺 在 氯甲酸乙酯 、 三乙胺 作用下， 以 氯仿 、 甲苯 为溶剂， 生成 O-isopropyl 2-tert-butoxy-5-fluorophenylthiocarbamate
  参考文献：
  名称：

  Synthesis of the Marine Sponge Derived β₂-Adrenoceptor Agonist S1319

  摘要：

  The marine sponge derived beta 2-adrenoceptor agonist S1319 has been synthesized following a six-step linear sequence. Central to the approach employed is the formation of a 7-lithiated-2,4-dialkoxybenzothiazole intermediate obtained via a directed-lithiation/benzyne-mediated cyclization reaction. The incorporation of a tert-butyl ether residue into the cyclization precursor for the pivotal ring-closing step has been shown to significantly increase the efficiency of the reaction by the suppression of a competing directed ortho-lithiation reaction.

  DOI：

  10.1021/ol0518840

文献信息

• [EN] PROCESS<br/>[FR] PROCÉDÉ
  申请人：ASTRAZENECA AB

  公开号：WO2012156693A1

  公开（公告）日：2012-11-22

  Processes for the preparation of the compound of formula (II) and intermediate compounds for use in the processes.

  用于配制化合物（II）的工艺和用于这些工艺的中间化合物的过程。
• [EN] BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY<br/>[FR] DERIVES DE BENZOTHIAZOLE AYANT UNE ACTIVITE D'AGONISTE DU BETA-2-ADRENORECEPTEUR
  申请人：NOVARTIS AG

  公开号：WO2004016601A1

  公开（公告）日：2004-02-26

  Compounds of Formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the ß2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式(I)中的化合物以自由形式、盐或溶剂形式存在，其中X具有规范中指示的含义，可用于治疗通过激活β2-肾上腺素受体预防或缓解的症状。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] COMBINAISON D'AGONISTES DE L'ADRENORECEPTEUR BETA2 DE LA BENZOTHIAZOL-2-ONE ET DE CORTICOSTEROIDES DANS LE TRAITEMENT DES MALADIES RESPIRATOIRES
  申请人：NOVARTIS AG

  公开号：WO2005074924A1

  公开（公告）日：2005-08-18

  A medicament comprising, separately or together, (A) a compound of Formula (I) in free or salt or solvate form, wherein X has the meaning as indicated in the specification; and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.

  一种药物，包括（A）公式（I）的化合物，其以自由形式或盐或溶剂形式分别或同时存在，其中X的含义如规范所示；以及（B）皮质类固醇，用于同时、顺序或分别治疗炎症性阻塞性呼吸道疾病，（A）与（B）的摩尔比为100:1至1:300。
• Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
  申请人：Cuenoud Bernard

  公开号：US20060106075A1

  公开（公告）日：2006-05-18

  Compounds of formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式(I)的化合物，包括自由形式、盐形式或溶剂合物形式，其中X的含义如规范中所示，可用于治疗通过激活β2-肾上腺素能受体预防或缓解的疾病。还描述了包含该化合物的制药组合物和制备该化合物的过程。
• ORGANIC COMPOUNDS
  申请人：CUENOUD Bernard

  公开号：US20150065490A1

  公开（公告）日：2015-03-05

  Compounds of formula I in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，无论是自由形式、盐形式或溶剂形式，其中X的意义在说明书中指示，可用于治疗通过激活β2-肾上腺素受体预防或缓解的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。